Advertisement

Inflammation

, Volume 41, Issue 2, pp 505–514 | Cite as

Intermedin1–53 Protects Cardiac Fibroblasts by Inhibiting NLRP3 Inflammasome Activation During Sepsis

  • Di Wu
  • Lin Shi
  • Pengyang Li
  • Xianqiang Ni
  • Jinsheng Zhang
  • Qing Zhu
  • Yongfen Qi
  • Bin Wang
ORIGINAL ARTICLE

Abstract

Sepsis is a disease that occurs as a result of systemic inflammatory response syndrome (SIRS) in response to an infection, contributing to multiple organ dysfunction and a high mortality rate. Interleukin-lβ (IL-1β) is a cytokine that plays critical roles in inflammation and cardiac dysfunction during severe sepsis. Intermedin1–53 (IMD1–53) has been recently discovered to possess potential endogenous anti-inflammatory and strong cardiovascular protective effects. To investigate whether IMD1–53 can inhibit the NLRP3/caspase-1/IL-1β pathway to alleviate cardiac injury and rescue heart function, sepsis was induced in vivo by caecal ligation and puncture (CLP) surgery, and lipopolysaccharides were used as septic stressors for cardiac fibroblasts (CFs) in vitro. The expressions of IMD1–53 receptors in sepsis rat heart were increased. After IMD1–53 treatment, inflammation caused by sepsis in vivo was greatly reduced, as shown by the downregulation of apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), nucleotide-binding domain and leucine-rich repeat containing family, pyrin containing 3 (NLRP3), pro-IL-1β, caspase 1, and nuclear translocation of nuclear factor-κB (NF-kB) protein levels. In addition, cardiac function was significantly improved and mean arterial blood pressure (MABP) increased by 34.8% (P < 0.05) which almost back to normal. Surprisingly, IMD1–53 inhibited cell apoptosis, as caspase 3 activity and Bax expression was significantly reduced in the heart upon IMD1–53 treatment. IMD1–53 abolished the upregulation of ASC, NLRP3, and caspase 1 protein levels in CFs induced by lipopolysaccharide (LPS). IMD1–53 increased cell survival rates and inhibited IL-1β production in the cell culture medium. IMD1–53 can protect against inflammation and heart injury during sepsis via attenuating the NLRP3/caspase-1/IL-1β pathway.

KEY WORDS

intermedin1–53 sepsis heart failure NLRP3 inflammasome IL-1β cardiac fibroblasts 

Notes

Acknowledgments

This study is supported by the Research Foundation of the Aerospace Central Hospital (NO. YN201316 to Bin Wang) and the National Natural Sciences Foundation of China (NO. 81670434 to Yongfen Qi).

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflicts of interest.

References

  1. 1.
    Bell, D., and B.J. McDermott. 2008. Intermedin (adrenomedullin-2): a novel counter-regulatory peptide in the cardiovascular and renal systems. British Journal of Pharmacology 153 (Suppl 1): S247–S262.  https://doi.org/10.1038/sj.bjp.0707494.PubMedGoogle Scholar
  2. 2.
    Bone, R.C., R.A. Balk, F.B. Cerra, R.P. Dellinger, A.M. Fein, W.A. Knaus, R. Schein, et al. 1992. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Critical Care Medicine 20 (6): 864–874.CrossRefGoogle Scholar
  3. 3.
    Chang, J.R., X.H. Duan, B.H. Zhang, X. Teng, Y.B. Zhou, Y. Liu, Y.R. Yu, Y. Zhu, C.S. Tang, and Y.F. Qi. 2013. Intermedin1-53 attenuates vascular smooth muscle cell calcification by inhibiting endoplasmic reticulum stress via cyclic adenosine monophosphate/protein kinase A pathway. Experimental Biology and Medicine (Maywood, N.J.) 238 (10): 1136–1146.  https://doi.org/10.1177/1535370213502619.CrossRefGoogle Scholar
  4. 4.
    Fauvel, H., P. Marchetti, C. Chopin, P. Formstecher, and R. Neviere. 2001. Differential effects of caspase inhibitors on endotoxin-induced myocardial dysfunction and heart apoptosis. American Journal of Physiology. Heart and Circulatory Physiology 280 (4): H1608–H1614.CrossRefPubMedGoogle Scholar
  5. 5.
    Fearon, D.T., and R.M. Locksley. 1996. The instructive role of innate immunity in the acquired immune response. Science 272 (5258): 50–53.CrossRefPubMedGoogle Scholar
  6. 6.
    Fenton, K.E., and M.M. Parker. 2016. Cardiac function and dysfunction in sepsis. Clinics in Chest Medicine 37 (2): 289–298.  https://doi.org/10.1016/j.ccm.2016.01.014.CrossRefPubMedGoogle Scholar
  7. 7.
    Fisher, C.J., Jr., J.F. Dhainaut, S.M. Opal, J.P. Pribble, R.A. Balk, G.J. Slotman, T.J. Iberti, et al. 1994. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 271 (23): 1836–1843.CrossRefPubMedGoogle Scholar
  8. 8.
    Fisher, C.J., Jr., G.J. Slotman, S.M. Opal, J.P. Pribble, R.C. Bone, G. Emmanuel, D. Ng, D.C. Bloedow, M.A. Catalano, and Il-Ra Sepsis Syndrome Study Group. 1994. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Critical Care Medicine 22 (1): 12–21.CrossRefPubMedGoogle Scholar
  9. 9.
    Furian, T., C. Aguiar, K. Prado, R.V. Ribeiro, L. Becker, N. Martinelli, N. Clausell, L.E. Rohde, and A. Biolo. 2012. Ventricular dysfunction and dilation in severe sepsis and septic shock: relation to endothelial function and mortality. Journal of Critical Care 27 (3): 319 e319–319 e315.  https://doi.org/10.1016/j.jcrc.2011.06.017.CrossRefGoogle Scholar
  10. 10.
    Hagiwara, M., G. Bledsoe, Z.R. Yang, R.S. Smith Jr., L. Chao, and J. Chao. 2008. Intermedin ameliorates vascular and renal injury by inhibition of oxidative stress. American Journal of Physiology. Renal Physiology 295 (6): F1735–F1743.  https://doi.org/10.1152/ajprenal.90427.2008.PubMedCentralCrossRefPubMedGoogle Scholar
  11. 11.
    He, L., X. Peng, J. Zhu, X. Chen, H. Liu, C. Tang, Z. Dong, F. Liu, and Y. Peng. 2014. Mangiferin attenuate sepsis-induced acute kidney injury via antioxidant and anti-inflammatory effects. American Journal of Nephrology 40 (5): 441–450.  https://doi.org/10.1159/000369220.CrossRefPubMedGoogle Scholar
  12. 12.
    Hesse, D.G., K.J. Tracey, Y. Fong, K.R. Manogue, M.A. Palladino Jr., A. Cerami, G.T. Shires, and S.F. Lowry. 1988. Cytokine appearance in human endotoxemia and primate bacteremia. Surgery, Gynecology & Obstetrics 166 (2): 147–153.Google Scholar
  13. 13.
    Hong, Y., D.L. Hay, R. Quirion, and D.R. Poyner. 2012. The pharmacology of adrenomedullin 2/intermedin. British Journal of Pharmacology 166 (1): 110–120.  https://doi.org/10.1111/j.1476-5381.2011.01530.x.PubMedCentralCrossRefPubMedGoogle Scholar
  14. 14.
    Hubbard, W.J., M. Choudhry, M.G. Schwacha, J.D. Kerby, L.W. Rue 3rd, K.I. Bland, and I.H. Chaudry. 2005. Cecal ligation and puncture. Shock 24 (Suppl 1): 52–57.CrossRefPubMedGoogle Scholar
  15. 15.
    Kakkar, R., and R.T. Lee. 2010. Intramyocardial fibroblast myocyte communication. Circulation Research 106 (1): 47–57.  https://doi.org/10.1161/CIRCRESAHA.109.207456.PubMedCentralCrossRefPubMedGoogle Scholar
  16. 16.
    Khan, M.M., W.L. Yang, and P. Wang. 2015. Endoplasmic reticulum stress in sepsis. Shock 44 (4): 294–304.  https://doi.org/10.1097/SHK.0000000000000425.PubMedCentralCrossRefPubMedGoogle Scholar
  17. 17.
    Kinoshita, T., R. Imamura, H. Kushiyama, and T. Suda. 2015. NLRP3 mediates NF-kappaB activation and cytokine induction in microbially induced and sterile inflammation. PLoS One 10 (3): e0119179.  https://doi.org/10.1371/journal.pone.0119179.PubMedCentralCrossRefPubMedGoogle Scholar
  18. 18.
    Li, H., Y. Bian, N. Zhang, J. Guo, C. Wang, W.B. Lau, and C. Xiao. 2013. Intermedin protects against myocardial ischemia-reperfusion injury in diabetic rats. Cardiovascular Diabetology 12: 91.  https://doi.org/10.1186/1475-2840-12-91.PubMedCentralCrossRefPubMedGoogle Scholar
  19. 19.
    Luo, Y.P., L. Jiang, K. Kang, D.S. Fei, X.L. Meng, C.C. Nan, S.H. Pan, M.R. Zhao, and M.Y. Zhao. 2014. Hemin inhibits NLRP3 inflammasome activation in sepsis-induced acute lung injury, involving heme oxygenase-1. International Immunopharmacology 20 (1): 24–32.  https://doi.org/10.1016/j.intimp.2014.02.017.CrossRefPubMedGoogle Scholar
  20. 20.
    Makara, M.A., K.V. Hoang, L.P. Ganesan, E.D. Crouser, J.S. Gunn, J. Turner, L.S. Schlesinger, P.J. Mohler, and M.V. Rajaram. 2016. Cardiac electrical and structural changes during bacterial infection: an instructive model to study cardiac dysfunction in sepsis. Journal of the American Heart Association 5 (9).  https://doi.org/10.1161/JAHA.116.003820.
  21. 21.
    Mao, K., S. Chen, M. Chen, Y. Ma, Y. Wang, B. Huang, Z. He, et al. 2013. Nitric oxide suppresses NLRP3 inflammasome activation and protects against LPS-induced septic shock. Cell Research 23 (2): 201–212.  https://doi.org/10.1038/cr.2013.6.PubMedCentralCrossRefPubMedGoogle Scholar
  22. 22.
    McDonald, T.E., M.N. Grinman, C.M. Carthy, and K.R. Walley. 2000. Endotoxin infusion in rats induces apoptotic and survival pathways in hearts. American Journal of Physiology. Heart and Circulatory Physiology 279 (5): H2053–H2061.CrossRefPubMedGoogle Scholar
  23. 23.
    Merx, M.W., and C. Weber. 2007. Sepsis and the heart. Circulation 116 (7): 793–802.  https://doi.org/10.1161/CIRCULATIONAHA.106.678359.CrossRefPubMedGoogle Scholar
  24. 24.
    Morelli, A., S. De Castro, J.L. Teboul, M. Singer, M. Rocco, G. Conti, L. De Luca, et al. 2005. Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intensive Care Medicine 31 (5): 638–644.  https://doi.org/10.1007/s00134-005-2619-z.CrossRefPubMedGoogle Scholar
  25. 25.
    Ni, X., J. Zhang, C. Tang, and Y. Qi. 2014. Intermedin/adrenomedullin2: an autocrine/paracrine factor in vascular homeostasis and disease. Science China Life Sciences 57 (8): 781–789.  https://doi.org/10.1007/s11427-014-4701-7.CrossRefPubMedGoogle Scholar
  26. 26.
    Parrillo, J.E., M.M. Parker, C. Natanson, A.F. Suffredini, R.L. Danner, R.E. Cunnion, and F.P. Ognibene. 1990. Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Annals of Internal Medicine 113 (3): 227–242.CrossRefPubMedGoogle Scholar
  27. 27.
    Potz, B.A., F.W. Sellke, and M.R. Abid. 2016. Endothelial ROS and impaired myocardial oxygen consumption in sepsis-induced cardiac dysfunction. Journal of Intensive Critical Care 2 (1).Google Scholar
  28. 28.
    Rattarasarn, C. 1997. Hypoglycemia in sepsis: risk factors and clinical characteristics. Journal of the Medical Association of Thailand 80 (12): 760–766.PubMedGoogle Scholar
  29. 29.
    Rudiger, A., and M. Singer. 2007. Mechanisms of sepsis-induced cardiac dysfunction. Critical Care Medicine 35 (6): 1599–1608.  https://doi.org/10.1097/01.CCM.0000266683.64081.02.CrossRefPubMedGoogle Scholar
  30. 30.
    Sarkar, A., M. Duncan, J. Hart, E. Hertlein, D.C. Guttridge, and M.D. Wewers. 2006. ASC directs NF-kappaB activation by regulating receptor interacting protein-2 (RIP2) caspase-1 interactions. Journal of Immunology 176 (8): 4979–4986.CrossRefGoogle Scholar
  31. 31.
    Schroder, K., and J. Tschopp. 2010. The inflammasomes. Cell 140 (6): 821–832.  https://doi.org/10.1016/j.cell.2010.01.040.CrossRefPubMedGoogle Scholar
  32. 32.
    Teng, X., J. Song, G. Zhang, Y. Cai, F. Yuan, J. Du, C. Tang, and Y. Qi. 2011. Inhibition of endoplasmic reticulum stress by intermedin(1-53) protects against myocardial injury through a PI3 kinase-Akt signaling pathway. Journal of Molecular Medicine (Berlin, Germany) 89 (12): 1195–1205.  https://doi.org/10.1007/s00109-011-0808-5.CrossRefGoogle Scholar
  33. 33.
    Tissier, S., S. Lancel, X. Marechal, S. Mordon, F. Depontieu, A. Scherpereel, C. Chopin, and R. Neviere. 2004. Calpain inhibitors improve myocardial dysfunction and inflammation induced by endotoxin in rats. Shock 21 (4): 352–357.CrossRefPubMedGoogle Scholar
  34. 34.
    van Nieuwenhoven, F.A., and N.A. Turner. 2013. The role of cardiac fibroblasts in the transition from inflammation to fibrosis following myocardial infarction. Vascular Pharmacology 58 (3): 182–188.  https://doi.org/10.1016/j.vph.2012.07.003.CrossRefPubMedGoogle Scholar
  35. 35.
    Vieillard-Baron, A., V. Caille, C. Charron, G. Belliard, B. Page, and F. Jardin. 2008. Actual incidence of global left ventricular hypokinesia in adult septic shock. Critical Care Medicine 36 (6): 1701–1706.  https://doi.org/10.1097/CCM.0b013e318174db05.CrossRefPubMedGoogle Scholar
  36. 36.
    Wang, Y., J. Tian, H. Guo, Y. Mi, R. Zhang, and R. Li. 2016. Intermedin ameliorates IgA nephropathy by inhibition of oxidative stress and inflammation. Clinical and Experimental Medicine 16 (2): 183–192.  https://doi.org/10.1007/s10238-015-0351-8.CrossRefPubMedGoogle Scholar
  37. 37.
    Wu, R., S. Tang, M. Wang, X. Xu, C. Yao, and S. Wang. 2016. MicroRNA-497 induces apoptosis and suppresses proliferation via the Bcl-2/Bax-caspase9-caspase3 pathway and cyclin D2 protein in HUVECs. PLoS One 11 (12): e0167052.  https://doi.org/10.1371/journal.pone.0167052.PubMedCentralCrossRefPubMedGoogle Scholar
  38. 38.
    Wu, Y., J. Ren, B. Zhou, C. Ding, J. Chen, G. Wang, G. Gu, et al. 2015. Gene silencing of non-obese diabetic receptor family (NLRP3) protects against the sepsis-induced hyper-bile acidaemia in a rat model. Clinical and Experimental Immunology 179 (2): 277–293.  https://doi.org/10.1111/cei.12457.PubMedCentralCrossRefPubMedGoogle Scholar
  39. 39.
    Yang, S.M., J. Liu, and C.X. Li. 2014. Intermedin protects against myocardial ischemia-reperfusion injury in hyperlipidemia rats. Genetics and Molecular Research 13 (4): 8309–8319.  https://doi.org/10.4238/2014.October.20.7.CrossRefPubMedGoogle Scholar
  40. 40.
    Zhang, B., Y. Liu, Y.B. Sui, H.Q. Cai, W.X. Liu, M. Zhu, and X.H. Yin. 2015. Cortistatin inhibits NLRP3 Inflammasome activation of cardiac fibroblasts during sepsis. Journal of Cardiac Failure 21 (5): 426–433.  https://doi.org/10.1016/j.cardfail.2015.01.002.CrossRefPubMedGoogle Scholar
  41. 41.
    Zhang, B., Y. Liu, J.S. Zhang, X.H. Zhang, W.J. Chen, X.H. Yin, and Y.F. Qi. 2015. Cortistatin protects myocardium from endoplasmic reticulum stress induced apoptosis during sepsis. Molecular and Cellular Endocrinology 406: 40–48.  https://doi.org/10.1016/j.mce.2015.02.016.CrossRefPubMedGoogle Scholar
  42. 42.
    Zhang, J.S., Y.L. Hou, W.W. Lu, X.Q. Ni, F. Lin, Y.R. Yu, C.S. Tang, and Y.F. Qi. 2016. Intermedin1-53 protects against myocardial fibrosis by inhibiting endoplasmic reticulum stress and inflammation induced by homocysteine in apolipoprotein E-deficient mice. Journal of Atherosclerosis and Thrombosis 23 (11): 1294–1306.  https://doi.org/10.5551/jat.34082.PubMedCentralCrossRefPubMedGoogle Scholar
  43. 43.
    Zhang, W., X. Xu, R. Kao, T. Mele, P. Kvietys, C.M. Martin, and T. Rui. 2014. Cardiac fibroblasts contribute to myocardial dysfunction in mice with sepsis: the role of NLRP3 inflammasome activation. PLoS One 9 (9): e107639.  https://doi.org/10.1371/journal.pone.0107639.PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2017

Authors and Affiliations

  1. 1.The Peking University Aerospace School of Clinical MedicinePeking University Health Science CenterBeijingChina
  2. 2.The Peking University People’s HospitalBeijingChina
  3. 3.Texas Heart InstituteHoustonUSA
  4. 4.Key Laboratory of Molecular Cardiovascular Science, Ministry of EducationPeking University Health Science CenterBeijingChina
  5. 5.The First Affiliated Hospital of Shantou University Medical CollegeGuangdongChina

Personalised recommendations